Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Jul 16, 09:57 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Friday, July 06


News

United Kingdom Pharmaceutical Industry - Porter's Five Forces Strategy Analysis, With GSK and AstraZeneca Leading the Market - ResearchAndMarkets.com

GSK AZN +1 more GSK AZN AZN

United Kingdom Pharmaceutical Industry - Porter's Five Forces Strategy Analysis, With GSK and AstraZeneca Leading the Market - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Industry in UK - Porter's Five Forces Strategy Analysis" report has been added to ResearchAndMarkets.com's offering. The pharmaceutical industry in the UK has been witnessing a decline in recent years, even though the UK is home to many of the world's leading pharma companies such as GSK and AstraZeneca. The publisher analyzes the Pharmaceutical Industry in UK in the Michael Porter's Five Forces Analysis.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science
News

GlaxoSmithKline Stock’s June Performance

GSK GSK

British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. As it is a British company, it reports its revenue in British pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, July 05


News

Analysts’ Estimates and Recommendations for GSK in June

GSK

Analysts expect GlaxoSmithKline (GSK) to report revenue of ~7.1 billion British pounds during the second quarter, a 2.3% fall in year-over-year revenue compared to ~7.3 billion pounds during the second quarter of 2017. The company’s EPS are expected to be 25.96 pence during the second quarter.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, July 04


News

The Quarterly Performance of GSK’s Consumer Healthcare Segment

GSK

GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, Shingles vaccines, and established vaccines. The segment reported a 7% rise in YoY (year-over-year) revenue to ~1.2 billion British pounds during the first quarter. This rise followed a 13% rise in operating revenue offset by the 6% negative impact of foreign exchange during the quarter.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

PFE vs. GSK: Which Stock Is the Better Value Option? - July 4, 2018

GSK

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and GlaxoSmithKline (GSK). But which of these two companies is the best option for those looking for undervalued stocks? Investors should feel comfortable knowing that PFE likely has seen a stronger improvement to its earnings outlook than GSK has recently. But this is just one factor that value investors are interested in. The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors. Based on these metrics and many more, PFE holds a Value grade of B, while GSK has a Value grade of C. PFE is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that PFE is likely the superior value option right now.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, July 03


News

The Quarterly Performances of GlaxoSmithKline’s Business Segments

GSK GSK

GlaxoSmithKline’s (GSK) product portfolio is separated into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a rise in revenue at constant exchange rates across all three of its segments during the first quarter of 2018 compared to the first quarter of 2017. The Pharmaceuticals segment reported a 4% fall in YoY (year-over-year) revenue to ~4.0 billion British pounds during the first quarter, including a 2% rise in operating revenue offset by the 6% negative impact of foreign exchange.

Read Full Details

Topics:
  • Business
  • Financial
News

GlaxoSmithKline’s Quarterly Revenue Trend and Estimates

GSK GSK

GlaxoSmithKline (GSK) reported revenue of ~7.2 billion British pounds in the first quarter, a 2% fall compared to the ~7.3 billion pounds it reported during the first quarter of 2017. Its revenue included a 4% rise in operating revenue, which was more than offset by the 6% negative impact of foreign exchange during the quarter. GlaxoSmithKline reports its revenues under three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

Read Full Details

Topics:
  • Business
  • Financial
News

GlaxoSmithKline’s Valuation on June 29

GSK GSK

GlaxoSmithKline (GSK) is a global pharmaceutical company with a focus on sustainable growth through strategizing its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in British pounds.

Read Full Details

Topics:
  • Business
  • Financial

Monday, June 25


News

Clamour for GSK shingles shot points to bigger profits

GSK

GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought. While more than 1.5 million Americans have received Shingrix since the end of last year, others are having to wait, prompting the U.S. Centers for Disease Control and Prevention (CDC) to warn of shortages. GSK said it had increased deliveries significantly and was vaccinating people against shingles far faster than in the past, when Merck & Co's Zostavax was the only product available.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, June 22


News

Is GlaxoSmithKline a high-yield dividend star or a dangerous dog of the FTSE 100?

GSK GSK

You can get decent investing results by collecting dividends from high-yielding stocks and reinvesting them to compound your gains. However, that strategy only works well as long as the stocks you buy and hold have sustainable dividends. Is the 5%-plus dividend yield for pharmaceutical giant GlaxoSmithKline (LSE: GSK) sustainable? Cash flow generally supports profits well. But neither cash flow, earnings or the dividend have moved up over the past four years, suggesting that GlaxoSmithKline is struggling to grow. Recent product launches included Shingrix, Trelegy and Juluca, which, along with other new releases, are contributing to improvements in the firm’s adjusted operating margin. However, the problem of patent expiry still dogs the firm and sometimes it seems as if two steps back follow every two steps forward, as the recent stagnant dividend attests.

Read Full Details

Topics:
  • Business
  • Health
  • Financial